PTC Therapeutics, Inc.

PTCT Real Time Price USD

N/A

...

Overview

Financials

Forecast

Insiders

Institutions

Government

Ownership

News

Income

Balance Sheet

Cash Flow

Revenue Breakdown

Congress Trading

Recent trades of PTCT by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

PTCT Stock Insider Trading Activity

Name	Type	Shares	Price	Shares Held	Date	Reported

PTCT Stock Institutional Owners

Investor	Shares	Change in Shares	Market Value	Date	Reported

PTCT Derivatives Institutional Owners

Investor	Type	Shares	Change in Shares	Market Value	Date	Reported

Whale Activity

Recently reported changes by institutional investors

No Whale Activity for this ticker

Institutional Holdings Dashboard

Insider Trading

Quarterly net insider trading by PTCT's directors and management

Corporate Lobbying

Government lobbying spending instances

$210,000 Apr 21, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
$80,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
$90,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
$90,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
$500,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
$170,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations
$170,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations
$190,000 Feb 04, 2025 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
$570,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
$160,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
$190,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
$200,000 Jul 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
$370,000 Apr 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
$190,000 Apr 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
$180,000 Oct 20, 2021 Issue: None
$180,000 Jul 20, 2021 Issue: None
$180,000 Apr 20, 2021 Issue: None
$180,000 Jan 21, 2021 Issue: None
$180,000 Oct 29, 2020 Issue: None
$50,000 Jul 20, 2020 Issue: Health Issues
$50,000 Apr 26, 2020 Issue: Health Issues
$50,000 Feb 25, 2020 Issue: Health Issues
$20,000 Apr 17, 2019 Issue: Budget/Appropriations
$40,000 Apr 17, 2019 Issue: Budget/Appropriations
$30,000 Jan 22, 2019 Issue: Budget/Appropriations
$60,000 Jan 22, 2019 Issue: Budget/Appropriations
$10,000 Jan 16, 2019 Issue: None
$10,000 Oct 18, 2018 Issue: Health Issues Medicare/Medicaid
$30,000 Oct 18, 2018 Issue: Budget/Appropriations
$60,000 Oct 18, 2018 Issue: Budget/Appropriations
$30,000 Jul 20, 2018 Issue: Budget/Appropriations
$60,000 Jul 20, 2018 Issue: Budget/Appropriations
$30,000 Apr 20, 2018 Issue: Budget/Appropriations
$30,000 Apr 20, 2018 Issue: Budget/Appropriations
$30,000 Jan 17, 2018 Issue: Budget/Appropriations
$30,000 Jan 17, 2018 Issue: Budget/Appropriations
$30,000 Oct 18, 2017 Issue: Budget/Appropriations
$30,000 Oct 18, 2017 Issue: Budget/Appropriations
$30,000 Aug 09, 2017 Issue: Budget/Appropriations
$30,000 Aug 09, 2017 Issue: Budget/Appropriations
$30,000 Jul 18, 2017 Issue: Budget/Appropriations
$10,000 Apr 20, 2017 Issue: Health Issues
$30,000 Apr 19, 2017 Issue: Budget/Appropriations
$10,000 Jan 19, 2017 Issue: Budget/Appropriations
$30,000 Jan 12, 2017 Issue: Budget/Appropriations
$30,000 Oct 20, 2016 Issue: Health Issues

Corporate Lobbying

Estimated quarterly lobbying spending

Revenue Breakdown

PTCT Revenue by Segment or Geography

By Segment

By Geography

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard

PTCT Income Statement

PTCT Balance Sheet

PTCT Cash Flow

U.S. Patents

New patents grants

Patent Title: Heteroaryl compounds for treating huntington's disease Nov. 12, 2024
Patent Title: Compounds for treating huntington's disease Oct. 01, 2024
Patent Title: Method for treating pancreatic cancer Jul. 02, 2024
Patent Title: Polymorphic forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Mar. 26, 2024
Patent Title: Heterocyclic and heteroaryl compounds for treating huntington's disease Jan. 02, 2024
Patent Title: 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Dec. 12, 2023
Patent Title: Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione Oct. 17, 2023
Patent Title: Compounds for treating huntington's disease Oct. 10, 2023
Patent Title: Compounds for treating spinal muscular atrophy Sep. 12, 2023
Patent Title: 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Sep. 05, 2023
Patent Title: Methods for modulating rna splicing Jul. 18, 2023
Patent Title: Heteroaryl compounds for treating huntington's disease Jun. 27, 2023
Patent Title: Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders Jun. 20, 2023
Patent Title: 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Jun. 06, 2023
Patent Title: Methods for treating huntington's disease May. 02, 2023
Patent Title: Method of inhibiting or reducing a viral infection Mar. 28, 2023
Patent Title: Methods for modifying rna splicing Mar. 21, 2023
Patent Title: Methods for modulating rna splicing Mar. 14, 2023
Patent Title: Methods for enriching alpha-tocotrienol from mixed tocol compositions Jan. 24, 2023
Patent Title: Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease Nov. 15, 2022
Patent Title: Dhodh inhibitor for use in treating hematologic cancers Oct. 04, 2022
Patent Title: Compounds for treating huntington's disease Aug. 09, 2022
Patent Title: Methods for treating huntington's disease Jul. 26, 2022
Patent Title: 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof Jul. 19, 2022
Patent Title: Methods for treating huntington's disease Jul. 12, 2022
Patent Title: Process for the production of alpha-tocotrienol and derivatives Apr. 26, 2022
Patent Title: Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Apr. 19, 2022
Patent Title: Methods for enriching alpha-tocotrienol from mixed tocol compositions Nov. 30, 2021
Patent Title: Substituted reverse pyrimidine bmi-1 inhibitors Nov. 23, 2021
Patent Title: 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Nov. 16, 2021
Patent Title: Methods of administering deflazacort therapy Aug. 10, 2021
Patent Title: Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers Jun. 01, 2021
Patent Title: Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders Apr. 20, 2021
Patent Title: 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Apr. 06, 2021
Patent Title: Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease Mar. 30, 2021
Patent Title: Processes for the preparation of substituted tetrahydro beta-carbolines Mar. 16, 2021
Patent Title: Gene therapy for aadc deficiency Jan. 26, 2021
Patent Title: Methods for treating huntington's disease Jan. 05, 2021
Patent Title: Methods for treating huntington's disease Dec. 29, 2020
Patent Title: Compounds for treating spinal muscular atrophy Dec. 01, 2020
Patent Title: Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy Dec. 01, 2020
Patent Title: Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Aug. 25, 2020
Patent Title: Methods for enriching alpha-tocotrienol from mixed tocol compositions Aug. 18, 2020
Patent Title: 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof Aug. 11, 2020
Patent Title: Treatment of pervasive developmental disorders with redox-active therapeutics Aug. 11, 2020
Patent Title: Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders Jul. 07, 2020
Patent Title: Methods for modulating the amount of rna transcripts Jun. 23, 2020
Patent Title: Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease Jun. 09, 2020
Patent Title: Methods for modulating rna splicing Jun. 02, 2020
Patent Title: Substituted pyridine and pyrazine bmi-1 inhibitors Mar. 10, 2020

Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

PTCT News

Recent insights relating to PTCT

CNBC Recommendations

Recent picks made for PTCT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PTCT

PTCT Analyst Ratings

PTCT Stock Forecasts

...

... Highest Price Target
... Median Price Target
... Lowest Price Target

PTCT Analyst Forecasts

Analyst	Firm	Current	Previous	Date

Frequently Asked Questions

Is $PTCT stock a Buy, Sell, or Hold?
What is the price target for $PTCT stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

PTCT Top Shareholders

Shareholder	Shares Held

PTCT Options Owners

Shareholder	Security	Underlying Shares

Frequently Asked Questions

Who owns $PTCT stock?
Who owns the most shares of $PTCT stock?
What funds own $PTCT stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

PTCT Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.

Score Breakdown

Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.